Article info
Clinical and epidemiological research
Extended report
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
- Correspondence to Dr G R Burmester, Clinic for Rheumatology and Clinical Immunology, Charité Humboldt University, Schumannstrasse 20/21, 10117 Berlin, Germany; gerd.burmester{at}charite.de
Citation
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
Publication history
- Accepted January 2, 2009
- First published January 15, 2009.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Web Only Data 68/12/1863
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Burmester et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.